A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.

Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A

Hormones (Athens, Greece)1 Jan 2015Cited by 78 (Europe PMC)

PMID25885106DOI10.1007/bf03401383PepBankPUB-25885106

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, 12 weeks of liraglutide significantly reduced body weight (intention-to-treat).
In plain wordsIn obese women with newly diagnosed PCOS, 12 weeks of liraglutide was linked to weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 32
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Body weight change
−2.52 kg
both treatment arms
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The main outcome was change in body weight.
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510601
02HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, weight loss with liraglutide did not differ significantly from metformin (intention-to-treat).
In plain wordsIn obese women with newly diagnosed PCOS, weight loss with liraglutide was not significantly different from weight loss with metformin.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, liraglutide vs metformin
Study
n = 32
Comparator
Metformin 1000 mg BID
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The main outcome was change in body weight.
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510602
03HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, 12 weeks of liraglutide significantly reduced BMI (intention-to-treat).
In plain wordsIn obese women with newly diagnosed PCOS, 12 weeks of liraglutide was linked to a lower BMI.
Peptide
Liraglutide
Outcome
DecreaseBMI change
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
BMI change
−0.98 kg/m(2)
both treatment arms
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510603
04HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, the BMI reduction with liraglutide did not differ significantly from metformin.
In plain wordsIn obese women with newly diagnosed PCOS, BMI fell about as much with liraglutide as with metformin.
Peptide
Liraglutide
Outcome
No significant changeBMI change, liraglutide vs metformin
Study
n = 32
Comparator
Metformin 1000 mg BID
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510604
05HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, 12 weeks of liraglutide significantly reduced waist circumference (intention-to-treat).
In plain wordsIn obese women with newly diagnosed PCOS, 12 weeks of liraglutide was linked to a smaller waist.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference change
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Waist circumference change
−3.38 cm
both treatment arms
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510605
06HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, the waist circumference reduction with liraglutide did not differ significantly from metformin.
In plain wordsIn obese women with newly diagnosed PCOS, waist size fell about as much with liraglutide as with metformin.
Peptide
Liraglutide
Outcome
No significant changeWaist circumference change, liraglutide vs metformin
Study
n = 32
Comparator
Metformin 1000 mg BID
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510606
07HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, 12 weeks of liraglutide significantly reduced whole-body fat mass (intention-to-treat).
In plain wordsIn obese women with newly diagnosed PCOS, 12 weeks of liraglutide was linked to less body fat.
Peptide
Liraglutide
Outcome
DecreaseWhole-body fat mass change
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Whole-body fat mass change
−1.26%
both treatment arms
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510607
08HumanRandomized controlled trialEfficacy outcome
In obese women with newly diagnosed PCOS, the fat mass reduction with liraglutide did not differ significantly from metformin.
In plain wordsIn obese women with newly diagnosed PCOS, body fat fell about as much with liraglutide as with metformin.
Peptide
Liraglutide
Outcome
No significant changeWhole-body fat mass change, liraglutide vs metformin
Study
n = 32
Comparator
Metformin 1000 mg BID
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510608
09HumanRandomized controlled trialEfficacy outcome
In the subgroup of obese women with PCOS, insulin resistance and severe obesity, BMI fell more with liraglutide than with metformin.
In plain wordsIn a small subgroup of obese women with PCOS and insulin resistance, BMI fell more with liraglutide than with metformin.
Peptide
Liraglutide
Outcome
DecreaseBMI change in subgroup with insulin resistance and severe obesity
Study
n = 9
Comparator
Metformin 1000 mg BID
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Mean BMI decrease
2.13 kg/m(2)
liraglutide, subgroup
Mean BMI decrease
0.62 kg/m(2)
metformin, subgroup
Source sentences
Summary
However, in a subgroup of patients (n=9) with insulin resistance (HOMA(IR) >2), severe obesity and higher odds ratio for the metabolic syndrome (OR=3.9), the patients fared much better with liraglutide than with metformin (mean BMI decreased 2.13 kg/m(2) vs. 0.62 kg/m(2), respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin).
Report a problemFND-2588510609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT05702905

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Peking University First Hospitaln = 759 May 2023 to est. 30 Jun 2025

PCOS (Polycystic Ovary Syndrome) · Semaglutide

Trial page ClinicalTrials.govUpdated 25 Mar 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.